Cover Image
市場調查報告書

EpiCast 到Report:第二型糖尿病 - 至2024年的流行病學預測

EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2025

出版商 GlobalData 商品編碼 274255
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast 到Report:第二型糖尿病 - 至2024年的流行病學預測 EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2025
出版日期: 2016年06月06日 內容資訊: 英文 69 Pages
簡介

糖尿病,是全球最常見的非傳染性疾病,全世界的患者總數,估計有3億8,700萬人。其中90%以上是第二型糖尿病。在全球主要9個國家 (美國、法國、德國、義大利、西班牙、英國、日本、中國、印度),第二型糖尿病確診的患者數,從2014年的113,536,653人,今後10年達到148,340,916人,預計年度成長率為3.07%。

本報告提供全球主要9個國家的第二型糖尿病調查分析,疾病的背景,危險因素和共生病症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • EU主要5個國家
    • 日本
    • 中國、印度
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 第二型糖尿病的流行病學預測
    • 第二型糖尿病和確診的患者數
    • 第二型糖尿病和確診的患者數 (各年齡)
    • 第二型糖尿病和確診的患者數 (性別)
    • 第二型糖尿病和確診的患者數 (年齡標準化) 、等
  • 討論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER120-16

Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body's inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90% of all diabetes cases around the world; type 1 diabetes (T1D) and gestational diabetes make up the remaining 10% of the cases. Risk factors for T2D are broadly categorized as either modifiable or non-modifiable risk factors. Lifestyle factors such as obesity, physical inactivity, and dietary habits are modifiable risk factors, whereas family history and advancing age are non-modifiable risk factors. T2D is also associated with several comorbidities, such as CKD, CVD, hypertension, and dyslipidemia, which can worsen the quality of life of the patient, and can lead to poor therapeutic outcomes. Diabetes is one of the most common non-communicable diseases worldwide and is an escalating public health problem globally.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of T2D in the 9MM, from 116,871,808 diagnosed prevalent cases in 2015 to 151,907,657 diagnosed prevalent cases in 2025, with an Annual Growth Rate (AGR) of 3.00%. The projected increase in the diagnosed prevalent cases of T2D across all the markets covered in this analysis is attributed to the actual increase in the incidence of T2D along with the change in population demographics in the respective markets.

GlobalData epidemiologists utilized country-specific diagnosed prevalence data for T2D across the 9MM. Additionally, the epidemiological forecast for the diagnosed prevalent cases of T2D in the 9MM is supported by nationally representative longitudinal historical data obtained from studies in respective countries published in peer-reviewed journals or national healthcare databases, which provide a detailed insight into the epidemiology of the disease in these markets.

Scope

  • The Type 2 Diabetes (T2D) EpiCast Report provides an overview of the risk factors and global trends of T2D in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). It includes a 10-year epidemiology forecast of T2D diagnosed prevalent cases segmented by age (in ten-year increments beginning at ages 20-30 years and ending at age 80 years and older), sex, and comorbidities including chronic kidney disease (CKD), cardiovascular disease (CVD), overweight/obesity, hypertension, and dyslipidemia in these nine markets.
  • The T2D epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

The T2D EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global T2D market.
  • Quantify patient populations in the global T2D market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for T2D therapeutics in each of the markets covered.
  • Identify the percentage of T2D diagnosed prevalent cases by age, sex, and comorbidities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
    • 3.3.3. Japan
    • 3.3.4. China and India
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used for Diagnosed Prevalence of T2D
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, Diagnosed Prevalent Cases of T2D
  • 3.5. Epidemiological Forecast for T2D (2015-2025)
    • 3.5.1. Diagnosed Prevalent Cases of T2D
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of T2D
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of T2D
    • 3.5.4. Age-Standardized Diagnosed Prevalence of T2D
    • 3.5.5. Prevalent Cases of Chronic Kidney Disease Among Diagnosed T2D Cases
    • 3.5.6. Prevalent Cases of Cardiovascular Disease Among Diagnosed T2D Cases
    • 3.5.7. Prevalent Cases of Overweight/Obesity Among Diagnosed T2D Cases
    • 3.5.8. Prevalent Cases of Hypertension Among Diagnosed T2D Cases
    • 3.5.9. Prevalent Cases of Dyslipidemia Among Diagnosed T2D Cases
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for T2D
  • Table 2: 9MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of T2D
  • Table 3: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CKD Among Diagnosed Prevalent Cases of T2D
  • Table 4: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CVD Among Diagnosed Prevalent Cases of T2D
  • Table 5: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Overweight and Obesity Among Diagnosed Prevalent Cases of T2D
  • Table 6: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Hypertension Among Diagnosed Prevalent Cases of T2D
  • Table 7: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Dyslipidemia Among Diagnosed Prevalent Cases of T2D
  • Table 8: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Table 9: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N (Row %), 2015
  • Table 10: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N (Row %), 2015

List of Figures

  • Figure 1: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages ≥20 Years, N, 2015-2025
  • Figure 2: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2015
  • Figure 3: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages ≥20 Years, N, 2015
  • Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of T2D (%), Ages ≥20 Years, by Sex, 2015
  • Figure 5: 9MM, Prevalent Cases of CKD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 6: 8MM, Prevalent Cases of CVD Among Diagnosed T2D Cases, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 7: 9MM, Prevalent Cases of Overweight/Obesity Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015
  • Figure 8: 9MM, Prevalent Cases of Hypertension Among Diagnosed T2D, Both Sexes, Ages ≥20Years, N, 2015
  • Figure 9: 8MM, Prevalent Cases of Dyslipidemia Among Diagnosed T2D, Both Sexes, Ages ≥20 Years, N, 2015
Back to Top